Related Experiment Video

Updated: Apr 16, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

742

Anti-inflammatory Strategies to Prevent Diabetic Cardiovascular Disease

I Jialal1, S Devaraj2

  • 1Laboratory for Atherosclerosis and Metabolic Research, UC Davis Medical Center, Sacramento, California, USA.

Clinical Pharmacology and Therapeutics
|March 4, 2015
PubMed

Insights

Diabetes promotes inflammation, increasing cardiovascular risks. While many anti-inflammatory drugs reduce inflammation, only a few, including statins and metformin, demonstrably lower cardiovascular events (CVEs) in diabetic patients.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is characterized by a chronic proinflammatory state.
  • Inflammation plays a critical role in the development of vascular complications associated with diabetes.
  • Existing anti-inflammatory strategies often fail to translate into reduced cardiovascular events (CVEs) in diabetic populations.

Purpose of the Study:

  • To review the current understanding of inflammation in diabetic vascular complications.
  • To identify anti-inflammatory therapies proven to reduce cardiovascular events (CVEs) in diabetes.
  • To discuss emerging therapeutic approaches for managing inflammation and CVEs in diabetes.

Main Methods:

  • Literature review of studies investigating anti-inflammatory strategies in diabetes.
  • Analysis of clinical trial data on the efficacy of various anti-inflammatory agents in reducing CVEs.
  • Synthesis of evidence regarding the impact of specific drugs (statins, ARBs, metformin, pioglitazone) on cardiovascular outcomes.

Main Results:

  • Numerous anti-inflammatory strategies effectively reduce markers of inflammation in diabetes.
  • Only a limited number of anti-inflammatory interventions have demonstrated a significant reduction in cardiovascular events (CVEs).
  • Statins, angiotensin receptor blockers (ARBs), metformin, and pioglitazone are identified as key therapies reducing CVEs in diabetes.

Conclusions:

  • Targeting inflammation is crucial for preventing vascular complications in diabetes.
  • A select group of anti-inflammatory drugs offers proven cardiovascular benefits in diabetic patients.
  • Further research into novel therapies is warranted to improve cardiovascular outcomes in diabetes.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
623
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
879
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K